Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Auromed Ltd (532103)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532103 NSE: Pharmaceuticals & Drugs | Small Cap | Auromed Share Price
BSE Share Price
Not Listed
Not Listed
Auromed Ltd (532103)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532103 NSE: Pharmaceuticals & Drugs | Small Cap | Auromed Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.2
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
284.62%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
-
Equity
₹5.1 Cr.
Face Value
₹10
All Time Low / High
- / -
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'02 | Mar'03 | Mar'04 | Mar'05 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 0.1% | 0.1% | 0.3% | 1.5% | - |
Growth Parameters ⓘ |
|||||
| Sales ⓘ | 0.4 | 0.4 | 0.4 | 1.5 | 2 |
| Sales YoY Gr. | - | 8.1% | -2.5% | 284.6% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 0.1 | 0.1 |
| YoY Gr. | - | NA | 100% | 350% | - |
| BVPS (₹) ⓘ | 9.4 | 9.4 | 9.6 | 9.8 | 10.1 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | 0.1 | 0 |
| Cash Flow from Ops. ⓘ | -0.1 | -0 | -0.1 | 0.2 | - |
| Debt/CF from Ops. ⓘ | -0.3 | -1.1 | -0.1 | 0.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 59.5% | 284.6% | ||||
| Adj EPS ⓘ | NA | NA | NA | 350% | ||||
| BVPSⓘ | NA | NA | 1.4% | 1.9% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'02 | Mar'03 | Mar'04 | Mar'05 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0.1 | 0.2 | 0.9 | 0.9 |
| Op. Profit Mgn % ⓘ | 0.5 | 0.7 | -6.3 | 6.6 | NAN |
| Net Profit Mgn % ⓘ | 0.3 | 0.4 | 2.1 | 3.1 | 3.1 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 160 | 218 | 71 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 57 | 91 | 31 | 0 |
Valuation of Auromed - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
No Data To Display
Promoter's Holding & Share Pledging
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Auromed Ltd FAQs
The current trading price of Auromed on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Auromed stood at ₹0.00 Cr
The latest P/E ratio of Auromed as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Auromed as of 31-Dec-1969 is 0.00.
The 52-week high of Auromed is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Auromed is ₹1.50 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Auromed Ltd
Auromed was incorporated in March 1995 as a public limited company promoted by D Srinivasvaradhan. The company is in the process of establishing a multipurpose bulk drug and pharmaceutical manufacturing plant at Guduvancheri in Tamilnadu. It came out with a public issue in June 1996 to part-finance this project. The company manufactures bronopol BP, norfloxacin BP and diclofenac sodium BP, betaine base and betaine hydrochloride BP.
Bronopol will be exported to European countries for which the company has firm marketing tie-up with Transtech International, UK; Herman Gshutte & Co, Germany and Pharmaco, Germany. Betaine base and betaine hydrochloride will also be exported through marketing agreement with Perry Pharmaceuticals, UK; Lab-Tech Pharma, Switzerland and Webster Pharma Technique, France . Norfloxacin and diclofenac sodium will be marketed in the domestic market.
The registered office of the company is located at Srinilayam 1, Kannaiah Street, T Nagar Chennai in Tamil Nadu.
You have 42 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
